PLAY PODCASTS
77. ESMO 2023 - Non Small Cell Lung Cancer

77. ESMO 2023 - Non Small Cell Lung Cancer

Oncology for the Inquisitive Mind · Michael Fernando and Josh Hurwitz

November 2, 202332m 26s

Audio is streamed directly from the publisher (sphinx.acast.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

Non-small cell lung cancer continues to show massive promise with new trials, better designs and exciting utilisation of existing therapies. Michael and Josh explore immunotherapy in a "sandwich setting" where nivolumab is given before and after surgery. Datopotamab deruxtecan, the new kid on the block, takes on the second-line champion docetaxel. Who will win, and will docetaxel finally be dethroned? And potentially the most promising and exciting addition to this lineup is AZD7789, a new bispecific antibody TIM-3 being added to existing immunotherapy to try and resensitise cancer to PD-1 inhibitors!


Studies discussed in today's episode (subscription may be required)


For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]


Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/


Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.


Hosted on Acast. See acast.com/privacy for more information.